SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation D61804R

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Comparison of E-Health vs. In-Person Delivered Family Psychoeducation Treatment

As specified in the VA Uniform Services Handbook, Family Psycho-Education (FPE) treatment must be available to all Veterans with schizophrenia who could benefit, and their family members. This includes those receiving care at Community Based Outpatient Clinics (CBOCs), and at Psychosocial Rehabilitation and Recovery Centers (PRRCs), whether provided on site, by referral, or by telemental health. However, less than 5% of VA medical centers offer FPE. Clearly, a major challenge is to devise ways to deliver mental health treatments and services to Veterans who need them in ways that meet their needs and preferences. The proposed project will compare the use of a website to deliver FPE to that of in-person delivered FPE. The findings could have profound implications for the VA's ability to improve the reach, use, appeal, and effectiveness of FPE for Veterans with schizophrenia, by using an e-health model that facilitates family involvement.

NCT02032680 Schizophrenia Schizoaffective Disorder Behavioral: Web-based multi-family psychoeducational treatment Behavioral: In-persons multi-family psycho-educational treatment Other: Treatment as usual (TAU)
MeSH:Schizophrenia Psychotic Disorders
HPO:Psychosis Schizophrenia

The investigators' previous work has developed a model and guidelines to design e-health applications for persons with schizophrenia and others with cognitive impairments (e.g., Rotondi, VA RR&D D61804R), and developed a highly scalable intervention termed Schizophrenia On-line Access to Resources (SOAR) (Rotondi, R01 MH63484). --- D61804R ---

Primary Outcomes

Description: Illness symptom severity will be assessed using the Scale for the Assessment of Positive Symptoms (SAPS)(the primary patient positive symptoms outcome) and the Scale for the Assessment of Negative Symptoms (SANS) (the primary patient negative symptoms outcome).

Measure: Positive symptoms (Scale for the Assessment of Positive Symptoms)

Time: Outcome will be assessed at 12 months (end of treatment)


HPO Nodes